Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT [sunitinib].
Phase of Trial: Phase IV
Latest Information Update: 20 Aug 2012
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.